Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

AAEON Biopharma, Inc.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
A

AEON Biopharma, Inc.

$0.29Close · Oct 6, 2026
  • Overview
  • Financial statements
  • Metrics
    • Revenue & profit
    • Revenue by segment
    • Launches
    • Revenue concentration
    • Margins
    • Contracted revenue
    • Off-balance-sheet commitments
    • Cash flow
    • Cash & debt
    • Earnings per share
    • P/E ratio
    • Share count & dilution
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • Insider Transactions
Loading financial graphs

Metrics

Revenue & profit
Revenue by segment
Margins
Contracted revenue
Cash flow
Cash & debt
Earnings per share
Share count & dilution

Metrics

Compare cash generated by the business, spending on long-lived assets, and what remains afterward.Formula: Free cash flow = operating cash flow − capital expenditures
$
20252022202320242025-30M-20M-10M0
    • Capex: purchases of property, plant and equipment
    • Capex: purchases of property, plant and equipment
    Latest period 2025. Operating cash flow -17.3M. Capex -4K. Free cash flow -17.3M.
    Operating cash flowCapexFree cash flow
    Compare the company’s cash cushion with its borrowings. Negative net cash means debt is greater than cash.Formula: Net cash = cash − debt
    202620222023202420252026020M40M60M80M100M120M
        Latest period 2026. Cash 3.4M. Debt 1.8M.
        CashDebtNet cash
        Profit for each share over the trailing 12 months, adjusted for stock splits.Formula: Earnings available to common shareholders ÷ weighted-average shares
        $/shareUsing split history cached 2026-10-06; assuming no new splits
        202520222023202420250.001,000.002,000.003,000.004,000.005,000.00
          • Earnings period 2022-01-01 to 2022-12-31. Shares as of 2022-12-31: 138,825,356 source shares.
          • Earnings period 2024-01-01 to 2024-12-31. Shares as of 2024-12-31: 555,511 source shares.
          • Earnings period 2025-01-01 to 2025-12-31. Shares as of 2025-12-31: 12,105,902 source shares.
          Latest period FY 2025. EPS (TTM) -3.24.
          EPS (TTM)
          How much investors pay for each dollar of the company’s yearly earnings. It is not useful when the company has no profit.Formula: Share price ÷ trailing 12-month EPS
          Using split history cached 2026-10-06; assuming no new splits
          20252022202320242025-25x-20x-15x-10x-5x0x
            • Earnings period 2022-01-01 to 2022-12-31. Shares as of 2022-12-31: 138,825,356 source shares. Nearby weekly price on 2022-12-30.
            • Earnings period 2024-01-01 to 2024-12-31. Shares as of 2024-12-31: 555,511 source shares. Nearby weekly price on 2025-01-03.
            • Earnings period 2025-01-01 to 2025-12-31. Shares as of 2025-12-31: 12,105,902 source shares. Nearby weekly price on 2026-01-02.
            Latest period FY 2025. P/E ratio -0.3x.
            P/E ratio
            See how the number of shares changes over time. More shares can mean each existing share owns a smaller slice of the company.Formula: Outstanding shares = issued shares − treasury shares Share-count growth = (current shares ÷ previous shares − 1) × 100%
            Stock split history may be out of date.
            202620222023202420252026050M100M
            2025-02-26: Reverse stock split 1-for-72
                Latest period 2026. Shares outstanding 26.3M. Class detail unavailable 26.3M.
                Class detail unavailableStock split